© 2003 by Oxford University Press
© 2003 Oxford University Press
ARTICLE |
Magnetic Resonance Spectroscopic Pharmacodynamic Markers of the Heat Shock Protein 90 Inhibitor 17-Allylamino,17-Demethoxygeldanamycin (17AAG) in Human Colon Cancer Models
Affiliations of authors: Cancer Research UK Biomedical Magnetic Resonance Research Group, Department of Basic Medical Sciences, St. George's Hospital Medical School, London, U.K. (Y-LC, HT, MS, JRG); Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, Surrey, U.K. (UB, MIW, IRJ, PW); Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden Hospital, Sutton (LEJ, MOL, SMR).
Correspondence to: Yuen-Li Chung, PhD, Cancer Research UK Biomedical Magnetic Resonance Research Group, Department of Basic Medical Sciences, St. George's Hospital Medical School, Cranmer Terrace, London SW17 ORE, U.K. (e-mail: ychung{at}sghms.ac.uk).
Background: 17-Allylamino,17-demethoxygeldanamycin (17AAG) is a novel anticancer drug that inhibits heat shock protein 90 (Hsp90), resulting in proteasomal degradation of several oncogenic proteins. We used phosphorus magnetic resonance spectroscopy (31P-MRS) to determine whether 17AAG treatment leads to alterations in phospholipids that could serve as pharmacodynamic markers for tumor response to 17AAG. Methods: HCT116, HT29, and SW620 colon cancer cells were treated with 17AAG, and extracts were examined by 31P-MRS. HT29 cells were also treated with the active metabolite of 17AAG, 17-amino,17-demethoxygeldanamycin (17AG), or the inactive 17AAG analog NSC683666. MF-1 nude mice carrying HT29 xenografts were examined using in vivo 31P-MRS before and after 17AAG treatment; xenograft tumor extracts were examined by 31P-MRS and proton MRS (1H-MRS). Hsp90 client protein expression was determined by using western blots. Two-tailed t tests were used to compare metabolite concentrations and ratios, and a Mann-Whitney U test was used to compare proportions. All statistical tests were two-sided. Results: 17AAG treatment led to statistically significantly increased phosphocholine levels in all three cell lines (P = .02). 17AG treatment also increased phosphocholine levels in HT29 cells, whereas NSC683666 had no effect. The phosphomonoester/phosphodiester ratio was statistically significantly increased in the HT29 xenografts after 17AAG treatment relative to the pretreatment ratio (P = .02), whereas no statistically significant change was observed after vehicle treatment (P = .62). Statistically significant increases in phosphocholine, phosphoethanolamine, and valine levels were also observed in tumor extracts treated with 17AAG. Conclusions: Inhibition of Hsp90 by 17AAG resulted in altered phospholipid metabolism in cultured tumor cells and in tumor xenografts. The increases observed in phosphocholine and phosphomonoester levels suggest that these metabolites may have the potential to act as noninvasive pharmacodynamic markers for analyzing tumor response to treatment with 17AAG or other Hsp90 inhibitors.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Beloueche-Babari, J. C. Peak, L. E. Jackson, M.-Y. Tiet, M. O. Leach, and S. A. Eccles Changes in choline metabolism as potential biomarkers of phospholipase C{gamma}1 inhibition in human prostate cancer cells Mol. Cancer Ther., May 1, 2009; 8(5): 1305 - 1311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Spratlin, N. J. Serkova, and S. G. Eckhardt Clinical Applications of Metabolomics in Oncology: A Review Clin. Cancer Res., January 15, 2009; 15(2): 431 - 440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ross, A. M. Najjar, M. Sankaranarayanapillai, W. P. Tong, K. Kaluarachchi, and S. M. Ronen Fatty acid synthase inhibition results in a magnetic resonance-detectable drop in phosphocholine Mol. Cancer Ther., August 1, 2008; 7(8): 2556 - 2565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. M. Claudino, A. Quattrone, L. Biganzoli, M. Pestrin, I. Bertini, and A. Di Leo Metabolomics: Available Results, Current Research Projects in Breast Cancer, and Future Applications J. Clin. Oncol., July 1, 2007; 25(19): 2840 - 2846. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G S Payne and M O Leach Applications of magnetic resonance spectroscopy in radiotherapy treatment planning Br. J. Radiol., September 1, 2006; 79(Special_Issue_1): S16 - S26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Workman, E. O. Aboagye, Y.-L. Chung, J. R. Griffiths, R. Hart, M. O. Leach, R. J. Maxwell, P. M. J. McSheehy, P. M. Price, and J. Zweit Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J Natl Cancer Inst, May 3, 2006; 98(9): 580 - 598. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. Weber Chaperoning Drug Development with PET J. Nucl. Med., May 1, 2006; 47(5): 735 - 737. [Full Text] [PDF]
|
|
|
|
|
|
M. Sankaranarayanapillai, W. P. Tong, D. S. Maxwell, A. Pal, J. Pang, W. G. Bornmann, J. G. Gelovani, and S. M. Ronen Detection of histone deacetylase inhibition by noninvasive magnetic resonance spectroscopy Mol. Cancer Ther., May 1, 2006; 5(5): 1325 - 1334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M.S. Al-Saffar, H. Troy, A. R. de Molina, L. E. Jackson, B. Madhu, J. R. Griffiths, M. O. Leach, P. Workman, J. C. Lacal, I. R. Judson, et al. Noninvasive Magnetic Resonance Spectroscopic Pharmacodynamic Markers of the Choline Kinase Inhibitor MN58b in Human Carcinoma Models Cancer Res., January 1, 2006; 66(1): 427 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Beloueche-Babari, L. E. Jackson, N. M.S. Al-Saffar, S. A. Eccles, F. I. Raynaud, P. Workman, M. O. Leach, and S. M. Ronen Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells Mol. Cancer Ther., January 1, 2006; 5(1): 187 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. D. McPhail, Y.-L. Chung, B. Madhu, S. Clark, J. R. Griffiths, L. R. Kelland, and S. P. Robinson Tumor Dose Response to the Vascular Disrupting Agent, 5,6-Dimethylxanthenone-4-Acetic Acid, Using In vivo Magnetic Resonance Spectroscopy Clin. Cancer Res., May 15, 2005; 11(10): 3705 - 3713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Beloueche-Babari, L. E. Jackson, N. M.S. Al-Saffar, P. Workman, M. O. Leach, and S. M. Ronen Magnetic Resonance Spectroscopy Monitoring of Mitogen-Activated Protein Kinase Signaling Inhibition Cancer Res., April 15, 2005; 65(8): 3356 - 3363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. WORKMAN Drugging the Cancer Kinome: Progress and Challenges in Developing Personalized Molecular Cancer Therapeutics Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 499 - 515. [Abstract] [PDF]
|
|
|
|
|
|
M. Lindskog, C. Spenger, J. Jarvet, A. Graslund, and P. Kogner Predicting Resistance or Response to Chemotherapy by Proton Magnetic Resonance Spectroscopy in Neuroblastoma J Natl Cancer Inst, October 6, 2004; 96(19): 1457 - 1466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Workman The critical role of molecular biomarkers in clinical trials of novel cancer therapeutics. AACR Meeting Abstracts, March 1, 2004; 2004(1): 1313 - 1313. [Abstract]
|
|